Approval · Notice of Compliance 35107 · 2025
LITHMAX: Notice of Compliance 35107
Issued April 1, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35107
- Date
- April 1, 2025
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Product Monograph reformatted to the Master Template. Update to Product Monograph (to align with supporting PM)
- Canadian reference product
- DURALITH (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LITHMAX | Not yet assigned | — |
Medicinal ingredients
- LITHIUM CARBONATE 300 MG per TAB